Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

Ernst-Wilhelm Radue; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Richard A Rudick; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Elizabeth Fisher; Athina Papadopoulou; Frances Lynn; Michael A Panzara; Alfred W Sandrock; SENTINEL Investigators; Per Soelberg Sørensen; Morten Bjørn Blinkenberg

doi:http://dx.doi.org/10.1016/j.jns.2010.02.012

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

Ernst-Wilhelm Radue, William H Stuart, Peter A Calabresi, Christian Confavreux, Steven L Galetta, Richard A Rudick, Fred D Lublin, Bianca Weinstock-Guttman, Daniel R Wynn, Elizabeth Fisher, Athina Papadopoulou, Frances Lynn, Michael A Panzara, Alfred W Sandrock, SENTINEL Investigators, Per Soelberg Sørensen, Morten Bjørn Blinkenberg

Department of Clinical Medicine

Research output: Contribution to journal › Journal article › Research › peer-review

52 Citations (Scopus)

Abstract

The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNbeta-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n=589) or placebo (n=582) intravenously every 4 weeks plus IFNbeta-1a 30 microg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNbeta-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNbeta-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNbeta-1a and increased in those receiving IFNbeta-1a alone (-277.5mm(3) versus 525.6mm(3); p

Original language	English
Journal	Journal of the Neurological Sciences
Volume	292
Issue number	1-2
Pages (from-to)	28-35
Number of pages	8
ISSN	0022-510X
DOIs	https://doi.org/10.1016/j.jns.2010.02.012
Publication status	Published - 15 May 2010

Access to Document

http://dx.doi.org/10.1016/j.jns.2010.02.012

Cite this

Radue, E-W., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Rudick, R. A., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Fisher, E., Papadopoulou, A., Lynn, F., Panzara, M. A., Sandrock, A. W., SENTINEL Investigators, Sørensen, P. S., & Blinkenberg, M. B. (2010). Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. Journal of the Neurological Sciences, 292(1-2), 28-35. https://doi.org/10.1016/j.jns.2010.02.012

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. / Radue, Ernst-Wilhelm; Stuart, William H; Calabresi, Peter A; Confavreux, Christian; Galetta, Steven L; Rudick, Richard A; Lublin, Fred D; Weinstock-Guttman, Bianca; Wynn, Daniel R; Fisher, Elizabeth; Papadopoulou, Athina; Lynn, Frances; Panzara, Michael A; Sandrock, Alfred W; SENTINEL Investigators ; Sørensen, Per Soelberg; Blinkenberg, Morten Bjørn.

In: Journal of the Neurological Sciences, Vol. 292, No. 1-2, 15.05.2010, p. 28-35.

Research output: Contribution to journal › Journal article › Research › peer-review

Radue, E-W, Stuart, WH, Calabresi, PA, Confavreux, C, Galetta, SL, Rudick, RA, Lublin, FD, Weinstock-Guttman, B, Wynn, DR, Fisher, E, Papadopoulou, A, Lynn, F, Panzara, MA, Sandrock, AW, SENTINEL Investigators, Sørensen, PS & Blinkenberg, MB 2010, 'Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis', Journal of the Neurological Sciences, vol. 292, no. 1-2, pp. 28-35. https://doi.org/10.1016/j.jns.2010.02.012

Radue, Ernst-Wilhelm ; Stuart, William H ; Calabresi, Peter A ; Confavreux, Christian ; Galetta, Steven L ; Rudick, Richard A ; Lublin, Fred D ; Weinstock-Guttman, Bianca ; Wynn, Daniel R ; Fisher, Elizabeth ; Papadopoulou, Athina ; Lynn, Frances ; Panzara, Michael A ; Sandrock, Alfred W ; SENTINEL Investigators ; Sørensen, Per Soelberg ; Blinkenberg, Morten Bjørn. / Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. In: Journal of the Neurological Sciences. 2010 ; Vol. 292, No. 1-2. pp. 28-35.

@article{7a9c464864c84a13a514e9d5dc905885,

title = "Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis",

abstract = "The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNbeta-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n=589) or placebo (n=582) intravenously every 4 weeks plus IFNbeta-1a 30 microg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNbeta-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNbeta-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNbeta-1a and increased in those receiving IFNbeta-1a alone (-277.5mm(3) versus 525.6mm(3); p",

author = "Ernst-Wilhelm Radue and Stuart, {William H} and Calabresi, {Peter A} and Christian Confavreux and Galetta, {Steven L} and Rudick, {Richard A} and Lublin, {Fred D} and Bianca Weinstock-Guttman and Wynn, {Daniel R} and Elizabeth Fisher and Athina Papadopoulou and Frances Lynn and Panzara, {Michael A} and Sandrock, {Alfred W} and S{\o}rensen, {Per Soelberg} and S{\o}rensen, {Per Soelberg} and Blinkenberg, {Morten Bj{\o}rn}",

year = "2010",

month = may,

day = "15",

doi = "http://dx.doi.org/10.1016/j.jns.2010.02.012",

language = "English",

volume = "292",

pages = "28--35",

journal = "Journal of the Neurological Sciences",

issn = "0022-510X",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

AU - Radue, Ernst-Wilhelm

AU - Stuart, William H

AU - Calabresi, Peter A

AU - Confavreux, Christian

AU - Galetta, Steven L

AU - Rudick, Richard A

AU - Lublin, Fred D

AU - Weinstock-Guttman, Bianca

AU - Wynn, Daniel R

AU - Fisher, Elizabeth

AU - Papadopoulou, Athina

AU - Lynn, Frances

AU - Panzara, Michael A

AU - Sandrock, Alfred W

AU - SENTINEL Investigators

AU - Sørensen, Per Soelberg

AU - Blinkenberg, Morten Bjørn

PY - 2010/5/15

Y1 - 2010/5/15

N2 - The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNbeta-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n=589) or placebo (n=582) intravenously every 4 weeks plus IFNbeta-1a 30 microg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNbeta-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNbeta-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNbeta-1a and increased in those receiving IFNbeta-1a alone (-277.5mm(3) versus 525.6mm(3); p

AB - The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNbeta-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n=589) or placebo (n=582) intravenously every 4 weeks plus IFNbeta-1a 30 microg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNbeta-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNbeta-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNbeta-1a and increased in those receiving IFNbeta-1a alone (-277.5mm(3) versus 525.6mm(3); p

U2 - http://dx.doi.org/10.1016/j.jns.2010.02.012

DO - http://dx.doi.org/10.1016/j.jns.2010.02.012

M3 - Journal article

VL - 292

SP - 28

EP - 35

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -